IL10 Release upon PD-1 Blockade Sustains Immunosuppression in Ovarian Cancer
Purushottam Lamichhane(Mayo Clinic), Keith L. Knutson(WinnMed), Ellen L. Goode(Mayo Clinic in Arizona), Lavakumar Karyampudi(Mayo Clinic), Joshua Daum(Jacksonville College), Deborah Bahr(Mayo Clinic in Florida), Kimberly R. Kalli(Mayo Clinic), James Krempski(University of North Carolina at Chapel Hill), Barath Shreeder(Mayo Clinic), Martin J. Cannon(University of Arkansas for Medical Sciences), Matthew S. Block(Mayo Clinic in Arizona)
Cited by 169
Related Papers
Associations of Breast Cancer Risk Factors With Tumor Subtypes: A Pooled Analysis From the Breast Cancer Association Consortium Studies
|JNCI Journal of the National Cancer Institute|2010|716
Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer
|JNCI Journal of the National Cancer Institute|2015|441
Immune-Induced Epithelial to Mesenchymal Transition <i>In vivo</i> Generates Breast Cancer Stem Cells
|Cancer Research|2009|378
GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer
|Nature Genetics|2013|363
Tumor-Infiltrating Programmed Death Receptor-1+ Dendritic Cells Mediate Immune Suppression in Ovarian Cancer
|The Journal of Immunology|2011|250